CA2116947A1 - Composition and method for treating patients with hepatic disease - Google Patents
Composition and method for treating patients with hepatic diseaseInfo
- Publication number
- CA2116947A1 CA2116947A1 CA002116947A CA2116947A CA2116947A1 CA 2116947 A1 CA2116947 A1 CA 2116947A1 CA 002116947 A CA002116947 A CA 002116947A CA 2116947 A CA2116947 A CA 2116947A CA 2116947 A1 CA2116947 A1 CA 2116947A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- amino acids
- protein
- source
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Abstract
ABSTRACT OF THE DISCLOSURE
A composition is provided that provides a nutritionally complete, calorically-dense formulation suitable for use as a supplement or total enteral feeding. The composition is specifically tailored to meet the requirements of hepatic patients in need of nutritional support. In contrast to current hepatic formulas, the composition is ready-to-use and does not require reconstitution and admixing. The ready-to-use formula contains a protein source that contains at least 25% of its total protein content as free crystalline amino acids.
A composition is provided that provides a nutritionally complete, calorically-dense formulation suitable for use as a supplement or total enteral feeding. The composition is specifically tailored to meet the requirements of hepatic patients in need of nutritional support. In contrast to current hepatic formulas, the composition is ready-to-use and does not require reconstitution and admixing. The ready-to-use formula contains a protein source that contains at least 25% of its total protein content as free crystalline amino acids.
Description
?116~7 S P E C I F I C A T I O N
TITLE
'COMPOBITION AND METHO~ FOR TREATING PATIENT~ WITH
HEPATIC DISEABE"
BACKGROUND OF THE INVENTION
The present invention relates generally to methods and compositions for treating patients who have hepatic disease. More specifically, the present invention relates to an enteral composition specifically designed for patients with hepatic disease.
The liver, and its proper functioning, i5 of utmost importance to the survival of a patient. Because it is responsible for the metabolism of nearly all nutrients, and is the primary site for the inactivation of numerous toxins, the liver is one of the most important organs of the body. For example, the liver accounts for approximately 20% of the body's basal metabolism.
The liver extracts a majority of the amino acids, carbohydrates, lipids, vitamins, and minerals from portal circulation. These nutrients, extracted by the liver, are used as substrates or cofactors in all metabolic processes carried out in the liver. Synthesis of plasma proteins and bile secretion are additionally important processes carried out by the liver.
Due to a variety of insults and pathogens, the liver can become diseased. Liver disease is a broad classification encompassing a number of acute and chronic diseases. These diseases include: hepatitis (viral and non-viral); cirrhosis (alcoholic and non-alcoholic); and liver failure. Liver failure is perhaps the most severe disease and may be accompanied by a complex set of conditions including: hepatic encephalopathy;
TITLE
'COMPOBITION AND METHO~ FOR TREATING PATIENT~ WITH
HEPATIC DISEABE"
BACKGROUND OF THE INVENTION
The present invention relates generally to methods and compositions for treating patients who have hepatic disease. More specifically, the present invention relates to an enteral composition specifically designed for patients with hepatic disease.
The liver, and its proper functioning, i5 of utmost importance to the survival of a patient. Because it is responsible for the metabolism of nearly all nutrients, and is the primary site for the inactivation of numerous toxins, the liver is one of the most important organs of the body. For example, the liver accounts for approximately 20% of the body's basal metabolism.
The liver extracts a majority of the amino acids, carbohydrates, lipids, vitamins, and minerals from portal circulation. These nutrients, extracted by the liver, are used as substrates or cofactors in all metabolic processes carried out in the liver. Synthesis of plasma proteins and bile secretion are additionally important processes carried out by the liver.
Due to a variety of insults and pathogens, the liver can become diseased. Liver disease is a broad classification encompassing a number of acute and chronic diseases. These diseases include: hepatitis (viral and non-viral); cirrhosis (alcoholic and non-alcoholic); and liver failure. Liver failure is perhaps the most severe disease and may be accompanied by a complex set of conditions including: hepatic encephalopathy;
2 ~ 1 f;1'~7 hemorrhage; coagulapathy; ascites; jaundice; and hepatorenal syndrome.
Although many medical treatments have been devised for treating liver disease, due to the paradoxical relationship between hepatic function and metabolism, medical treatment of the liver disease is complex and difficult. Most, if not all, liver diseases require or benefit from nutritional management. Those diseases which are believed to benefit most from nutritional management, include alcoholic and non-alcoholic cirrhosis, obstructive jaundice, and in some situations acute liver failure. The goals of such nutritional therapies vary depending on disease and patient. The goals can be either restorative or supportive.
Liver disease can affect both hepatic cellular function and structure. In chronic conditions such as alcoholic cirrhosis, exposure to a toxicant promotes inflammation of the periportal areas of the liver. As a result, fibrosis develops and when sufficiently advanced, canaliculi become blocked. As a result of inadequate regional perfusion, hepatocyte degeneration occurs.
In an attempt to restore adequate circulation, portal hypertension develops. Portosystemic shunting of the blood results in chronic hypertension. Many of the ! ~ serious complications of liver disease are due to this event.
Portosystemic shunting allows many substances, for example, amino acids, fatty acids, ammonia, and others, to bypass the liver. These substances then flood the neurological system. Portosystemic shunting results in many clinical features including variceal changes and - encephalopathy.
' ' ~ 1 1 f~ 7 Many specific metabolic derangements are associated with liver disease. This is especially true of liver disease of a chronic nature. Such derangements include:
increased plasrna glucagon; hyperinsulinemia; increased plasma epinephrine and cortisol; decrease liver and muscle carbohydrate stores; accelerated gluconeogenesis;
hypoglycemia; hyperammonemia; increased plasma aromatic amino acid; increase plasma methionine, glutamine, asparagine, and histidine; and decreased plasma branched chain amino acids.
A number of hypotheses, mostly metabolism based, have been advanced concerning the pathogenesis of hepatic encephalopathy. For example, excess nitrogen (ammonium) production and accumulation of false neural transmitters have been advanced as possible causes.
Although a number of nutritional formulations designed for hepatic patients had been proposed none of the formulations, in the opinion of the inventors, function entirely satisfactorily. Such formulations include: Amin-Aid6q (Kendall-McGaw); and Travasorb~
Hepatic (Clintec Nutrition Company).
One disadvantage with these formulations is that they are not ready to use. Rather, they are powders that require admixing and reconstitution before use. Powders that require admixing create disadvantaqes including ! sterility, labor, and time concerns.
Although a ready-to-use formulation would be desirable and greatly preferred over a powder, there are difficulties in attempting to create a ready-to-use formulations. The difficulties have, to the best of the inventors' belief, prevented the creation of viable ready-to-use hepatic enteral formulations. The '': ` ' , ' . ~` ' ' ' ~ ' :
21 1 ~ 17 difficulties include the instability of solutions containing free crystalline amino acids.
There is therefore a need for an improved nutritional formulation for patients with liver disease.
SUMMARY OF THE INVENTION
The present invention provides in part, a ready-to-use enteral composition specifically designed for patients with liver disease. The composition is a nutritionally complete, calorically-dense formulation suitable for use as a supplement or total enteral feeding. The composition is specifically tailored to meet the requirements of hepatic patients in need of nutritional support. In contrast to current hepatic formulas, the composition is ready-to-use and does not require reconstitution and admixing.
To this end, the present invention provides a ready-to-use formula containing a protein source that contains at least 25% of its total protein content as free crystalline amino acids. Preferably, a majority of the protein source is present as free crystalline amino acids, i.e., greater than 50%. In an embodiment, approximately 75% of the protein is provided as free crystalline amino acids.
In an embodiment, the composition contains approximatelv 6% to about 16% of the calories as protein;
approximately 66 to about 88% of the calories as carbohydrate; and approximately 6 to about 18% as lipid.
Additionally, the composition preferably meets or exceeds 100% of the U.S. RDA for vitamins and minerals in lOOO
ml (1500 K cal) of product.
Preferably protein is provided in the form of a combination of free crystalline amino acids and high quality whey protein. Preferably the amino acid profiles ';,: ' ~; ' ,`, ,; ' ' . ~ ; ;, ~ ~ . . ;; ' ; , are rich in branched amino acids (approximately 40% to about 60% of the total amino acid content) and is low in aromatic and ammonia-generating amino acids (less than preferably 3% of the total amino acid content).
In an embodiment, the carbohydrate is supplied in the form of easily - digestible maltodextrin and starch.
In an embodiment lipid is supplied as a mixture of medium chain triglycerides (approximately 50% to about 75% of the lipid source), canola oil, corn oil, and soy lecithin. The lipid source also provides a balanced supply of essential fatty acids in a readily absorbable, oxidizable lipid source.
In an embodiment, the lipid has a ratio of omega-6 to omega-3 fatty acids of approximately 4:1.
Preferably, the composition is gluten free and low in sodium.
A method of treating hepatic patients is also provided by the present invention as well as a method for making nutritional formulations for hepatic patients.
Still further, an advantage of the present invention is to provide a composition that provides improved utilization and metabolism of both the omega-6 and omega-3 families.
An advantage of the present invention is that it provides a ready-to-use enteral diet specifically designed for patients with liver disease.
A further advantage of the present invention is that the composition of the present invention is specifically tailored to meet the requirements of hepatic diseased patients.
Additionally, an advantage of the present invention is to provide a stable, ready-to-use formula, including 2 ~ 7 a protein composition that comprises greater than 50% of its content as free crystalline amino acids.
Still further, an advantage of the present invention is that the composition of the present invention provides a protein content that is designed to meet nutritional requirements, promote muscle anabolism and minimize ammonium production, but limit intake in persons who are protein intolerant.
Furthermore, an advantage of the present invention is that it provides a composition including carbohydrates which are easily digestible and well absorbed.
Another advantage of the present invention is that in an embodiment, the composition is lactose-free thus eliminating the risk of developing symptoms of lactose intolerance. -Moreover, an advantage of the present invention is that the composition provides, in part, medium chain triglyceride that are well absorbed and a readily oxidizable sources of calories.
Still further, an advantage of the present invention is that the composition provides at least 100% of the U.S. RDA of vitamins and minerals.
Furthermore, an advantage of the present invention is that the composition meets the stress augmented needs of most patients. ~; -, Additional features and advantages of the present ~ -invention are described in, and will be apparent from, the detailed description of the presently preferred embodiments.
DETAILED DESCRIPTION
OF THE PRESENTLY PREFERRED EMBODIMENTS
The present invention provides an enteral composition specifically designed for patients with 2 1 1 ~ 7 , hepatic disease. The composition is nutritionally complete, calorically dense, and suitable as a supplement or a total enteral feeding - either by tube or orally.
The composition is specifically tailored to meet the requirements of hepatic patients in need of nutritional support.
In contrast to current hepatic formulations, the composition is ready-to-use. Because the product is shelf stable, it is not provided to the patient or healthcare practitioner as a powder. Therefore, the composition does not require reconstitution by the patient or healthcare practitioner. Although the composition is ready-to-use, it still provides sufficient free crystalline amino acids to function as a nutritionally complete hepatic composition.
In an embodiment, the composition contains:
approximately 6% to 16% of the calories as a protein source; approximately 66% to about 88% of the calories as a carbohydrate source; and approximately 6% to about 18~ of the calories as a lipid source. In a preferred embodiment, the composition comprises approximately 11%
of the calories as protein; approximately 77% of the calories as carbohydrate; and approximately 12% as lipid.
The composition is specifically tailored to meet the needs of liver diseased patients. As set forth in the background of the invention, these patients suffer the possibility of a number of derangements.
Because of the liver's fundamental role in the metabolism of nearly all nutrients, hepatic disease can easily compromise nutritional status. Therefore, malnutrition is common in hepatic diseased patients. It has been estimated, with respect to alcoholic cirrhotics with severe liver disease, that 10 to 100% of such ~ ~ 1 fi!3~7 patients are malnourished. See, McCulloush et al, Nutritional State in Liver Disease Assessment. Incidence and Mechanism of Malnutrition, Metabolism and Nutrition in Liver Disease, E. Holm et al (Editors) 1984, p. 5~15.
This malnutrition develops as a result of a number of factors including: anorexia; nutrient malabsorption and maldigestion; reduced food intake; and possibly increased energy expenditure.
Malabsorption also frequently occurs in patients with liver disease particularly in mal-nourished patients.
Fat malabsorption is frequent; in one study, 8 out of 13 malnourished cirrhotics demonstrated fat malabsorption.
Romiti et al, Malabsor~tion and Nutritional Abnormalities in Patients with Liver Disease, Ital. J. Gastroenterol., 151990; 22:118-123.
It is necessary for the hepatic composition of the present invention to provide adequate energy intake to support protein synthesis. If energy intakes are inadequate, amino acids will be used to support energy 20demands. Conversely, excess caloric intake will result in increased deposition of fat in the liver; this can result in further metabolic impairment of the liver. The composition of the present invention provides normal nutritional status and supports hepatocyte regeneration.
25Although most stable cirrhotic patients have no overt problems digesting and absorbing protein and amino acids, investigators have reported derangements in such patient's plasma amino acid profiles. See, Morgan et al, Plasma Amino Acid Patterns In Liver Disease, Gut 1982;
3023:362-370. This suggests altered tissue utilization of amino acids. For example, plasma levels of leucine, isoleucine, and valine concentrations in hepatic patients are low. Additionally, methionine and aromatic amino 2:L i 6.~7 acids, i.e., tryptophan, tyrosine, and phenylalanine, concentrations are elevated. The composition of the present invention is specifically tailored to correct these abnormalities.
The composition of the present invention provides 6% to 16% of the composition, by caloric content, as protein. In a preferred embodiment 11% of the composition, by caloric content, is provided as protein or 40 g of protein per liter (1500 kcals).
Pursuant to the present invention, the protein comprises at least 25% and preferably 50% free crystalline amino acids. In a preferred embodiment, almost 75% of the protein is free crystalline amino acids. It has been found that by providing approximately 20%-25% of the protein as whey or other protein, a free amino acid rich protein source that is sufficiently stable can be provided.
The protein is preferably provided as a mixture of specific essential and non-essential amino acids and whey protein. The amino acid profile is rich in branched chain amino acids, preferably approximately 40 to about 60~, and most preferably 50~, and low in ammonotelic amino acids (3%) in order to offset the amino acid derangements associated with hepatic disease. The total protein content is designed to meet the nutritional requirements, promote muscle anabolism, and minimize ammonia production, but limit intake in persons who are protein intolerant.
The use of enriched branched amino acids is advantageous especially with respect to treating hepatic encephalopathy. It is believed that branched chain amino acids can either improve recovery from or, in combination with other therapy, improve such treatment.
~ 1 ~ 6 .') '1 7 Additionally, branched chain amino acids can decrease protein catabolism, increase synthesis of hepatic and muscle protein, and serve as energy substrates for muscle tissues. Ammonia production may also be reduced when branched chain amino acids are given as a substrate.
Further, branched chain amino acid can improve nitrogen balance.
During bouts of encephalopathy, protein restrictions below that required to maintain body stores, is often prescribed (less than 0.8 grams protein per Kg per day).
This, however, often results in negative nitrogen balance and additional loss of the lean body mass, ultimately contributing to further decline in nutritional and perhaps disease status. Accordingly, pursuant to the present invention, protein intake is carefully matched to the requirements to achieve optimal repletion with minimum negative clinical consequences. The amino acid profiles are customized to meet protein requirements and correct disease related changes in amino acid metabolism.
One of the principal metabolic defects in patients with liver disease is glucose intolerance. Elevations in glucagon, free fatty acids, and growth hormone are commonly observed in such patients and may serve to sustain high insulin levels and exacerbate glucose intolerance.
The composition of the present invention provides 66% to about 88% of the caloric content as carbohydrates.
In a preferred embodiment, the composition provides 77%
of the calories, or 290 grams of carbohydrates per liter (1500 kcals) are provided. In a preferred embodiment, the carbohydrates are provided in the form of maltodextrin and modified corn starch. These are easily digested and well absorbed.
2 ~ 1 6 ~ 47 Additionally, preferably, the composition is virtually lactose free. This eliminates the risk of the hepatic patients developing symptoms of lactose intolerance.
With respect to the llpid content, primary metabolic derangement of lipid metabolism in liver disease patient is lipid malabsorption. The cause of fat malabsorption may vary depending on the nature and severity of the liver disease. Non-alcoholic cirrhotics manifest normal gut histology while alcoholic cirrhotics show some evidence of jejunal damage. In both populations there is likely to be a reduction in bile salt synthesis, which also contributes to fat malabsorption.
In an embodiment, the composition of the present invention provides approximately 6 to about 18% of the calories as lipid. However, the composition could provide up to 25~ of the calories as lipid. In a preferred embodiment, the composition provides 12% of the caloric content, or 21 g lipid per liter (1500 kcals), in the form of lipids. In a preferred embodiment, the lipid content comprises a blend of medium chain triglyceride oil and long chain fatty acids.
Preferably, the blend of medium chain triglycerides to long chain triglycerides is l:1 to about 3:1. In a preferred embodiment, a 66:34% blend of medium chain ! .: triglyceride oil and long chain fatty acids is provided.
Medium chain triglycerides are well absorbed and a readily oxidizable source of calories. The substitution of medium chain triglycerides for long chain fatty acids, the inventors believe, will alleviate steatorrhea in some patients. In a number of hepatic patients - believed to be at least lO~ - steatorrhea is severe.
1 6 9 ~ '~
To provide essential fatty acids, in an embodiment, canola oil, milk fat, corn oil, and/or soy lecithin are provided. Linoleic and linolenic acid are provided preferably in a proportion of 3:1 to 5:1 and, most preferably, 4:1.
Hepatic patients have, typically, abnormalities of vitamin nutriture. However, assessment of vitamin and mineral status of hepatic patients is very difficult.
Commonly used plasma measurements may be profoundly altered by portosystemic shunting and hepatocyte degeneration. Depressed synthesis of visceral proteins may also influence plasma concentrations of vitamins, therefore, it is difficult to accurately characterize in a hepatic patient the severity of vitamin and mineral deficiencies.
However, it is clear that in hepatic patients, widespread suboptimal vitamin nurture is common. In general, hepatic stores of riboflavin, nicotinamide, pantothenic acid, and Vitamins B6, B12, and A are often depleted. See, Leevy et al, Vitamin and Liver Iniury, Am. J. Clin. Nutr. 1970; 23: 493-499. The absorption of all fat soluble vitamins is also adversely affected by hepatic diseased.
Vitamin A status is often impaired in liver disease with severity and type of the disease being significant determinants of its gravity. Fat malabsorption secondary to bile acid deficiency, may also contribute to the development of vitamin A deficiency.
Normally, Vitamin D3 is transported to hepatic tissue. In the liver, Vitamin D3 is converted to 25-hydroxy Vitamin D3. The active form of the vitamin (1, 25 dihydroxy Vitamin D3) is due to a hydroxylation step that occurs in the kidney. Liver disease impairs the . .
21 l ~'l 7 export of 25 hydroxy Vitamin D3 from the liver. See, Hepner G. et al, Abnormal Vitamin D Metabolism in Patients With Cirrhosis, Am. J. Dig. Dis., 1976; 21:527-535. Even though hepatic patients have normal serum levels of Vitamin D, they may therefore have reduced tissue stores.
Likewise, vitamin E status may be compromised by hepatic disease. This is particularly true with patients with malabsorption and diminished bile secretion.
Vitamin K status may also be compromised. This may be attributed to both malabsorption and cholestasis.
Water soluble vitamin nutriture may be similarly deranged particularly in the case of pyridoxine, thiamine, folate, riboflavin, and vitamin B12. Folate deficiency is the most common aberration in hepatic disease patients, especially alcoholic cirrhotics.
Clinically, anemia can develop in 3 to 6 weeks as a result of subnormal folate intake.
Deficiency of vitamin B12 can also develop in chronic liver disease.
Mineral nutriture may also be abnormal in patients with liver disease. Liver enzymes require as cofactors a number of trace elements, i.e. zinc, copper, nickel, selenium, chromium, and cobalt. Cirrhosis can readily deplete liver stores of these minerals, particularly zinc ! : and copper. Deficiencies or depletion may contribute to poor tissue repair and possibly neurological abnormalities.
Hyponatremia is relatively common in cirrhotic patients. This state develops in conjunction with an increase in the total body sodium pool which results in fluid retention. IncrPased sodium retention appears to result from increase aldosterone production. It is : :
t~)~47 necessary to restrict sodium intake to reduce ascites and edema.
Hypokalemia occurs frequently among cirrhotic patients. If not managed properly, hypokalemic alkalosis 5develops and hepatic encephalopathy may develop or worsen. Therefore, control of dietary intake of potassium relative to other minerals is vital.
Due to hepatic disease, calcium, phosphorus, and magnesium stores are also depleted. This depletion can 10be linked to a number of derangements, e.g., metabolic bone disease.
The present invention provides preferably in 1500 kcal (1000 mls) at least 100% U.S. RDA of all vitamins except vitamin C. Vitamin C is provided at at least 150%
15of the U.S. RDA to meet stress augmented needs in most patients.
Additionally the composition provides 100% of U.S.
RDA of calcium, phosphorus, magnesium, copper, iodine, iron, and zinc in 1500 kcals (1000 millimeters). In a 20preferred embodiment manganese is provided in concentrations of approximately 4 milligrams per 1500 kcals. Additionally, the composition also provides preferably approximately 400 mg Choline per 1500 kcals.
Additionally, approximately 80 milligrams sodium, 25330 milligrams potassium, and 375 milligrams chloride are provided per 250 ml. These concentrations allow flexibility in electrolyte management.
Little is known about the specific taurine and carnitine status or requirements for patients with liver 30disease. Taurine stores have been found to be depressed in patients with malabsorption syndromes. Additionally, liver malfunction is known to impair taurine synthesis.
Biosynthesis of carnitine may also be reduced when liver function is abnormal. Preferably, the composition of the present invention provides approximately 120 mg taurine and 120 mg carnitine per 1500 kcals.
By way of example, and not limitation, an example 5 of the composition of the present will now be given.
COMPOSITION:
1000 ml Protein (Nx5.8) g 40.00 Carbohydrate 9 290.00 Fat 9 21.20 Minerals 9 8.00 Moisture 9 761.60 Energy Kcal1500.00 KJ6280.00 Vitamin A IU5000.00 mcg RE 1500.00 Vitamin D IU400.00 mcg1 0.00 Vitamin E IU 30.00 Vitamin K mcg120.00 Vitamin C mg 96.00 Thiamine (B1) mg 1.52 Ribofiavin (B2) mg 1.72 Niacin (PP) mg 20.p0 Vitamin B6 mg 2.00 Folic Acid mcg400.00 . `
Pantoth. Acid mg 10.00 Vitamin B12 mcg6.00 Biotin mcg300.00 Choline mg400.00 Taurine mg120.00 L-Carnitine mg120.00 Soaiium mg320.00 , ~ . . . . . .
,~ i 1 ~ 9 1 7 Potassium mg1320.00 Chloride mg1500.00 Caicium mg1000.00 Phosphorus mg1000.00 Magnesium mg400.00 Copper mg 2.00 lodine mcg152.00 Iron mg 18.00 Manganese mg 4.00 1 0 Zinc mg 15.20 Density= 1125g/Liter pH 6.8 FAT COMPOSITION:
1 5 1000 ml Total fat 9 21.2 MCT 9 13.76 Canola Oil 9 4.16 C:orn Oil 9 1.12 Milk Fat 9 1.12 Lecithin 9 1.12 Linoleic Acid 9 1.58 Vitamin E IU 30 Vltamin E: linolelc = 19 lU/gm -~ ~:
PERCENTAGE COMPOSITION OF FAT: -MCT 66% (63% of energy from fat~
Canola oll 19% (20% of energy from fat) Corn oil 5% (5.5% of energy from fat) 3 0 Milk Fat 5% (5.5% of energy from fat) Lecithin _~ (6% of enerav from fat) Total 100% Total 100%
ll6~7 FATTY ACID COMPOSITION (CALCULATED FROM STANDARD VALUES):
Fany acid composition Calculated from standard values (% of total fattv acids) Saturated Butyric acid (C4:0)0.13 0.03 Caproic acid (C6:0)0.72 0.14 Caprylic acid (C8:0) 38.36 7.42 Capric acid (C,0:0) 27.02 5.23 1 0 Lauric acid (cl2 o) 1.43 0.28 Myristic acid (Cl4:0) 0.47 o.09 Palmitic acid (Cl6:0) 2.80 0.S4 Stearic acid (C,8:0) 1.16 0.22 Total saturated 72.09 l3.95 Unsaturated Palmitoleic acid (C,6:1) 0.25 0.05 Oleic acid (C~B:1) 16.74 3.24 Linoleic acid (C,a:2) 8.38 1.62 Linolenic acid (Cl8:3) 2.16 0.42 Erucic acid (C22:1) 0 40 0.08 Total unsaturated 27.93 5.41 Protein Source: Free Amino Acid 77%
Whey 23%
Nitrogen to energy ratio (9 N/kcal): 1:217 Nitrogen to non-protein energy ratio (9 N/kcal): 1 :194 ' :" -2 1 1 ~ 9 Ll 7 AMINO ACID COMPOSITION:
~QQ~ç~ 1500 Kcal250 ml1000 ml L-Leucine gm 0.62 9.32 2.33 9.32 i-lsoleucine gm 0.51 7.72 1.93 7.72 L-Valine gm 0.41 6.20 1.55 6.20 L-Lysine gm 0.33 5.00 1.25 5.00 L-Arginine gm 0.32 4.80 1.20 4.80 L-Prollne gm 0.17 2.48 0.62 2.48 L-Glutamic acid gm 0.14 2.08 0.52 2.08 1 0 L-Alanine gm 0.13 1.88 0.47 1.88 L-Threonine gm o.10 1.s2 0.38 1.52 L-Histidine gm 0.10 1.44 0.36 1.44 L-Aspartic acid gm 0.07 1.04 0.26 1.04 Glycine gm 0.05 0.76 0.19 0.76 L-Serine gm 0.04 0.64 0.16 0.64 L-Methionine gm 0.04 0.56 0.14 0.56 L-Phenylalanine gm 0.03 0.40 0.10 0.40 ~ -L-Tyrosine gm 0.02 0.32 0.08 0.32 L-Tryptophane gm 0.02 0.24 0.06 0.24 L-Cystine gm 0.01 0.16 0.04 0.16 MAJOR MINERALS
100 Kcal 1soo Kcal2s0 ml Sodium mg21.33 320.00 80.00320.00 mmol 0.93 13.92 3.48 13.92 2 5 Potassium mg88.00 1320.00 330.001320.00 mmol 2.25 33.76 8.44 33.76 Chloride mg100.00 1500.00 375.001500.00 mmol 2.82 42.32 10.58 42.32 Calcium mg66.67 1000.00 250.001000.00 3 0 mmol 1.67 25.00 6.25 25.00 Phosphorus mg66.67 1000.00 250.001000.00 mmol 2.15 32.24 8.06 32.24 .
!3 !1 7 Magnesium mg 26.67400.00100.00400.00 mmol1.1016.44 4.11 16.44 Ba~e excess (1) mmol0.365.36 1.34 5.36 Renal sol~e load (2)mOsm21.20318.00 29.50 318.00 ELECTROLYTE RATIOS
Na/K (3) : 0.4 (Na ~ K)/CI (3) : 1.1 Ca/P (4) : 1.0 FORMULA OSMOLARITY/OSMOLALITY
Osmolarity 525 mOsm/1 Osmolality 690 mOsm/kg H2O
The osmolarity of such liquid diets is important.
Because hypertonic diets are a cause of diarrhea and intestinal discomfort in patient on enteral feeding, hyperosmolar formulas initially have to be fed diluted and only gradually be increased to full strength. When a patient is not taking a formula full strength, he meets neither his energy nor his protein, mineral, and vitamin needs. There is also evidence that hypertonic foods have a deleterious effect on the gastrointestinal tract.
The osmolarity of the composition is preferably at least 500 mOsm/l and, in a preferred embodiment, 525 mOsm/l (690 mOsm/kg of water). This is hypertonic with serum (osmolarity 260-280 mOsm/ml, osmolali'y 280-300 mosmol/kg of water) and should not be expected to cause any problems.
It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present invention and without diminishing its attendant advantages. It is therefore intended that such changes and modifications be covered by the appended claims.
Although many medical treatments have been devised for treating liver disease, due to the paradoxical relationship between hepatic function and metabolism, medical treatment of the liver disease is complex and difficult. Most, if not all, liver diseases require or benefit from nutritional management. Those diseases which are believed to benefit most from nutritional management, include alcoholic and non-alcoholic cirrhosis, obstructive jaundice, and in some situations acute liver failure. The goals of such nutritional therapies vary depending on disease and patient. The goals can be either restorative or supportive.
Liver disease can affect both hepatic cellular function and structure. In chronic conditions such as alcoholic cirrhosis, exposure to a toxicant promotes inflammation of the periportal areas of the liver. As a result, fibrosis develops and when sufficiently advanced, canaliculi become blocked. As a result of inadequate regional perfusion, hepatocyte degeneration occurs.
In an attempt to restore adequate circulation, portal hypertension develops. Portosystemic shunting of the blood results in chronic hypertension. Many of the ! ~ serious complications of liver disease are due to this event.
Portosystemic shunting allows many substances, for example, amino acids, fatty acids, ammonia, and others, to bypass the liver. These substances then flood the neurological system. Portosystemic shunting results in many clinical features including variceal changes and - encephalopathy.
' ' ~ 1 1 f~ 7 Many specific metabolic derangements are associated with liver disease. This is especially true of liver disease of a chronic nature. Such derangements include:
increased plasrna glucagon; hyperinsulinemia; increased plasma epinephrine and cortisol; decrease liver and muscle carbohydrate stores; accelerated gluconeogenesis;
hypoglycemia; hyperammonemia; increased plasma aromatic amino acid; increase plasma methionine, glutamine, asparagine, and histidine; and decreased plasma branched chain amino acids.
A number of hypotheses, mostly metabolism based, have been advanced concerning the pathogenesis of hepatic encephalopathy. For example, excess nitrogen (ammonium) production and accumulation of false neural transmitters have been advanced as possible causes.
Although a number of nutritional formulations designed for hepatic patients had been proposed none of the formulations, in the opinion of the inventors, function entirely satisfactorily. Such formulations include: Amin-Aid6q (Kendall-McGaw); and Travasorb~
Hepatic (Clintec Nutrition Company).
One disadvantage with these formulations is that they are not ready to use. Rather, they are powders that require admixing and reconstitution before use. Powders that require admixing create disadvantaqes including ! sterility, labor, and time concerns.
Although a ready-to-use formulation would be desirable and greatly preferred over a powder, there are difficulties in attempting to create a ready-to-use formulations. The difficulties have, to the best of the inventors' belief, prevented the creation of viable ready-to-use hepatic enteral formulations. The '': ` ' , ' . ~` ' ' ' ~ ' :
21 1 ~ 17 difficulties include the instability of solutions containing free crystalline amino acids.
There is therefore a need for an improved nutritional formulation for patients with liver disease.
SUMMARY OF THE INVENTION
The present invention provides in part, a ready-to-use enteral composition specifically designed for patients with liver disease. The composition is a nutritionally complete, calorically-dense formulation suitable for use as a supplement or total enteral feeding. The composition is specifically tailored to meet the requirements of hepatic patients in need of nutritional support. In contrast to current hepatic formulas, the composition is ready-to-use and does not require reconstitution and admixing.
To this end, the present invention provides a ready-to-use formula containing a protein source that contains at least 25% of its total protein content as free crystalline amino acids. Preferably, a majority of the protein source is present as free crystalline amino acids, i.e., greater than 50%. In an embodiment, approximately 75% of the protein is provided as free crystalline amino acids.
In an embodiment, the composition contains approximatelv 6% to about 16% of the calories as protein;
approximately 66 to about 88% of the calories as carbohydrate; and approximately 6 to about 18% as lipid.
Additionally, the composition preferably meets or exceeds 100% of the U.S. RDA for vitamins and minerals in lOOO
ml (1500 K cal) of product.
Preferably protein is provided in the form of a combination of free crystalline amino acids and high quality whey protein. Preferably the amino acid profiles ';,: ' ~; ' ,`, ,; ' ' . ~ ; ;, ~ ~ . . ;; ' ; , are rich in branched amino acids (approximately 40% to about 60% of the total amino acid content) and is low in aromatic and ammonia-generating amino acids (less than preferably 3% of the total amino acid content).
In an embodiment, the carbohydrate is supplied in the form of easily - digestible maltodextrin and starch.
In an embodiment lipid is supplied as a mixture of medium chain triglycerides (approximately 50% to about 75% of the lipid source), canola oil, corn oil, and soy lecithin. The lipid source also provides a balanced supply of essential fatty acids in a readily absorbable, oxidizable lipid source.
In an embodiment, the lipid has a ratio of omega-6 to omega-3 fatty acids of approximately 4:1.
Preferably, the composition is gluten free and low in sodium.
A method of treating hepatic patients is also provided by the present invention as well as a method for making nutritional formulations for hepatic patients.
Still further, an advantage of the present invention is to provide a composition that provides improved utilization and metabolism of both the omega-6 and omega-3 families.
An advantage of the present invention is that it provides a ready-to-use enteral diet specifically designed for patients with liver disease.
A further advantage of the present invention is that the composition of the present invention is specifically tailored to meet the requirements of hepatic diseased patients.
Additionally, an advantage of the present invention is to provide a stable, ready-to-use formula, including 2 ~ 7 a protein composition that comprises greater than 50% of its content as free crystalline amino acids.
Still further, an advantage of the present invention is that the composition of the present invention provides a protein content that is designed to meet nutritional requirements, promote muscle anabolism and minimize ammonium production, but limit intake in persons who are protein intolerant.
Furthermore, an advantage of the present invention is that it provides a composition including carbohydrates which are easily digestible and well absorbed.
Another advantage of the present invention is that in an embodiment, the composition is lactose-free thus eliminating the risk of developing symptoms of lactose intolerance. -Moreover, an advantage of the present invention is that the composition provides, in part, medium chain triglyceride that are well absorbed and a readily oxidizable sources of calories.
Still further, an advantage of the present invention is that the composition provides at least 100% of the U.S. RDA of vitamins and minerals.
Furthermore, an advantage of the present invention is that the composition meets the stress augmented needs of most patients. ~; -, Additional features and advantages of the present ~ -invention are described in, and will be apparent from, the detailed description of the presently preferred embodiments.
DETAILED DESCRIPTION
OF THE PRESENTLY PREFERRED EMBODIMENTS
The present invention provides an enteral composition specifically designed for patients with 2 1 1 ~ 7 , hepatic disease. The composition is nutritionally complete, calorically dense, and suitable as a supplement or a total enteral feeding - either by tube or orally.
The composition is specifically tailored to meet the requirements of hepatic patients in need of nutritional support.
In contrast to current hepatic formulations, the composition is ready-to-use. Because the product is shelf stable, it is not provided to the patient or healthcare practitioner as a powder. Therefore, the composition does not require reconstitution by the patient or healthcare practitioner. Although the composition is ready-to-use, it still provides sufficient free crystalline amino acids to function as a nutritionally complete hepatic composition.
In an embodiment, the composition contains:
approximately 6% to 16% of the calories as a protein source; approximately 66% to about 88% of the calories as a carbohydrate source; and approximately 6% to about 18~ of the calories as a lipid source. In a preferred embodiment, the composition comprises approximately 11%
of the calories as protein; approximately 77% of the calories as carbohydrate; and approximately 12% as lipid.
The composition is specifically tailored to meet the needs of liver diseased patients. As set forth in the background of the invention, these patients suffer the possibility of a number of derangements.
Because of the liver's fundamental role in the metabolism of nearly all nutrients, hepatic disease can easily compromise nutritional status. Therefore, malnutrition is common in hepatic diseased patients. It has been estimated, with respect to alcoholic cirrhotics with severe liver disease, that 10 to 100% of such ~ ~ 1 fi!3~7 patients are malnourished. See, McCulloush et al, Nutritional State in Liver Disease Assessment. Incidence and Mechanism of Malnutrition, Metabolism and Nutrition in Liver Disease, E. Holm et al (Editors) 1984, p. 5~15.
This malnutrition develops as a result of a number of factors including: anorexia; nutrient malabsorption and maldigestion; reduced food intake; and possibly increased energy expenditure.
Malabsorption also frequently occurs in patients with liver disease particularly in mal-nourished patients.
Fat malabsorption is frequent; in one study, 8 out of 13 malnourished cirrhotics demonstrated fat malabsorption.
Romiti et al, Malabsor~tion and Nutritional Abnormalities in Patients with Liver Disease, Ital. J. Gastroenterol., 151990; 22:118-123.
It is necessary for the hepatic composition of the present invention to provide adequate energy intake to support protein synthesis. If energy intakes are inadequate, amino acids will be used to support energy 20demands. Conversely, excess caloric intake will result in increased deposition of fat in the liver; this can result in further metabolic impairment of the liver. The composition of the present invention provides normal nutritional status and supports hepatocyte regeneration.
25Although most stable cirrhotic patients have no overt problems digesting and absorbing protein and amino acids, investigators have reported derangements in such patient's plasma amino acid profiles. See, Morgan et al, Plasma Amino Acid Patterns In Liver Disease, Gut 1982;
3023:362-370. This suggests altered tissue utilization of amino acids. For example, plasma levels of leucine, isoleucine, and valine concentrations in hepatic patients are low. Additionally, methionine and aromatic amino 2:L i 6.~7 acids, i.e., tryptophan, tyrosine, and phenylalanine, concentrations are elevated. The composition of the present invention is specifically tailored to correct these abnormalities.
The composition of the present invention provides 6% to 16% of the composition, by caloric content, as protein. In a preferred embodiment 11% of the composition, by caloric content, is provided as protein or 40 g of protein per liter (1500 kcals).
Pursuant to the present invention, the protein comprises at least 25% and preferably 50% free crystalline amino acids. In a preferred embodiment, almost 75% of the protein is free crystalline amino acids. It has been found that by providing approximately 20%-25% of the protein as whey or other protein, a free amino acid rich protein source that is sufficiently stable can be provided.
The protein is preferably provided as a mixture of specific essential and non-essential amino acids and whey protein. The amino acid profile is rich in branched chain amino acids, preferably approximately 40 to about 60~, and most preferably 50~, and low in ammonotelic amino acids (3%) in order to offset the amino acid derangements associated with hepatic disease. The total protein content is designed to meet the nutritional requirements, promote muscle anabolism, and minimize ammonia production, but limit intake in persons who are protein intolerant.
The use of enriched branched amino acids is advantageous especially with respect to treating hepatic encephalopathy. It is believed that branched chain amino acids can either improve recovery from or, in combination with other therapy, improve such treatment.
~ 1 ~ 6 .') '1 7 Additionally, branched chain amino acids can decrease protein catabolism, increase synthesis of hepatic and muscle protein, and serve as energy substrates for muscle tissues. Ammonia production may also be reduced when branched chain amino acids are given as a substrate.
Further, branched chain amino acid can improve nitrogen balance.
During bouts of encephalopathy, protein restrictions below that required to maintain body stores, is often prescribed (less than 0.8 grams protein per Kg per day).
This, however, often results in negative nitrogen balance and additional loss of the lean body mass, ultimately contributing to further decline in nutritional and perhaps disease status. Accordingly, pursuant to the present invention, protein intake is carefully matched to the requirements to achieve optimal repletion with minimum negative clinical consequences. The amino acid profiles are customized to meet protein requirements and correct disease related changes in amino acid metabolism.
One of the principal metabolic defects in patients with liver disease is glucose intolerance. Elevations in glucagon, free fatty acids, and growth hormone are commonly observed in such patients and may serve to sustain high insulin levels and exacerbate glucose intolerance.
The composition of the present invention provides 66% to about 88% of the caloric content as carbohydrates.
In a preferred embodiment, the composition provides 77%
of the calories, or 290 grams of carbohydrates per liter (1500 kcals) are provided. In a preferred embodiment, the carbohydrates are provided in the form of maltodextrin and modified corn starch. These are easily digested and well absorbed.
2 ~ 1 6 ~ 47 Additionally, preferably, the composition is virtually lactose free. This eliminates the risk of the hepatic patients developing symptoms of lactose intolerance.
With respect to the llpid content, primary metabolic derangement of lipid metabolism in liver disease patient is lipid malabsorption. The cause of fat malabsorption may vary depending on the nature and severity of the liver disease. Non-alcoholic cirrhotics manifest normal gut histology while alcoholic cirrhotics show some evidence of jejunal damage. In both populations there is likely to be a reduction in bile salt synthesis, which also contributes to fat malabsorption.
In an embodiment, the composition of the present invention provides approximately 6 to about 18% of the calories as lipid. However, the composition could provide up to 25~ of the calories as lipid. In a preferred embodiment, the composition provides 12% of the caloric content, or 21 g lipid per liter (1500 kcals), in the form of lipids. In a preferred embodiment, the lipid content comprises a blend of medium chain triglyceride oil and long chain fatty acids.
Preferably, the blend of medium chain triglycerides to long chain triglycerides is l:1 to about 3:1. In a preferred embodiment, a 66:34% blend of medium chain ! .: triglyceride oil and long chain fatty acids is provided.
Medium chain triglycerides are well absorbed and a readily oxidizable source of calories. The substitution of medium chain triglycerides for long chain fatty acids, the inventors believe, will alleviate steatorrhea in some patients. In a number of hepatic patients - believed to be at least lO~ - steatorrhea is severe.
1 6 9 ~ '~
To provide essential fatty acids, in an embodiment, canola oil, milk fat, corn oil, and/or soy lecithin are provided. Linoleic and linolenic acid are provided preferably in a proportion of 3:1 to 5:1 and, most preferably, 4:1.
Hepatic patients have, typically, abnormalities of vitamin nutriture. However, assessment of vitamin and mineral status of hepatic patients is very difficult.
Commonly used plasma measurements may be profoundly altered by portosystemic shunting and hepatocyte degeneration. Depressed synthesis of visceral proteins may also influence plasma concentrations of vitamins, therefore, it is difficult to accurately characterize in a hepatic patient the severity of vitamin and mineral deficiencies.
However, it is clear that in hepatic patients, widespread suboptimal vitamin nurture is common. In general, hepatic stores of riboflavin, nicotinamide, pantothenic acid, and Vitamins B6, B12, and A are often depleted. See, Leevy et al, Vitamin and Liver Iniury, Am. J. Clin. Nutr. 1970; 23: 493-499. The absorption of all fat soluble vitamins is also adversely affected by hepatic diseased.
Vitamin A status is often impaired in liver disease with severity and type of the disease being significant determinants of its gravity. Fat malabsorption secondary to bile acid deficiency, may also contribute to the development of vitamin A deficiency.
Normally, Vitamin D3 is transported to hepatic tissue. In the liver, Vitamin D3 is converted to 25-hydroxy Vitamin D3. The active form of the vitamin (1, 25 dihydroxy Vitamin D3) is due to a hydroxylation step that occurs in the kidney. Liver disease impairs the . .
21 l ~'l 7 export of 25 hydroxy Vitamin D3 from the liver. See, Hepner G. et al, Abnormal Vitamin D Metabolism in Patients With Cirrhosis, Am. J. Dig. Dis., 1976; 21:527-535. Even though hepatic patients have normal serum levels of Vitamin D, they may therefore have reduced tissue stores.
Likewise, vitamin E status may be compromised by hepatic disease. This is particularly true with patients with malabsorption and diminished bile secretion.
Vitamin K status may also be compromised. This may be attributed to both malabsorption and cholestasis.
Water soluble vitamin nutriture may be similarly deranged particularly in the case of pyridoxine, thiamine, folate, riboflavin, and vitamin B12. Folate deficiency is the most common aberration in hepatic disease patients, especially alcoholic cirrhotics.
Clinically, anemia can develop in 3 to 6 weeks as a result of subnormal folate intake.
Deficiency of vitamin B12 can also develop in chronic liver disease.
Mineral nutriture may also be abnormal in patients with liver disease. Liver enzymes require as cofactors a number of trace elements, i.e. zinc, copper, nickel, selenium, chromium, and cobalt. Cirrhosis can readily deplete liver stores of these minerals, particularly zinc ! : and copper. Deficiencies or depletion may contribute to poor tissue repair and possibly neurological abnormalities.
Hyponatremia is relatively common in cirrhotic patients. This state develops in conjunction with an increase in the total body sodium pool which results in fluid retention. IncrPased sodium retention appears to result from increase aldosterone production. It is : :
t~)~47 necessary to restrict sodium intake to reduce ascites and edema.
Hypokalemia occurs frequently among cirrhotic patients. If not managed properly, hypokalemic alkalosis 5develops and hepatic encephalopathy may develop or worsen. Therefore, control of dietary intake of potassium relative to other minerals is vital.
Due to hepatic disease, calcium, phosphorus, and magnesium stores are also depleted. This depletion can 10be linked to a number of derangements, e.g., metabolic bone disease.
The present invention provides preferably in 1500 kcal (1000 mls) at least 100% U.S. RDA of all vitamins except vitamin C. Vitamin C is provided at at least 150%
15of the U.S. RDA to meet stress augmented needs in most patients.
Additionally the composition provides 100% of U.S.
RDA of calcium, phosphorus, magnesium, copper, iodine, iron, and zinc in 1500 kcals (1000 millimeters). In a 20preferred embodiment manganese is provided in concentrations of approximately 4 milligrams per 1500 kcals. Additionally, the composition also provides preferably approximately 400 mg Choline per 1500 kcals.
Additionally, approximately 80 milligrams sodium, 25330 milligrams potassium, and 375 milligrams chloride are provided per 250 ml. These concentrations allow flexibility in electrolyte management.
Little is known about the specific taurine and carnitine status or requirements for patients with liver 30disease. Taurine stores have been found to be depressed in patients with malabsorption syndromes. Additionally, liver malfunction is known to impair taurine synthesis.
Biosynthesis of carnitine may also be reduced when liver function is abnormal. Preferably, the composition of the present invention provides approximately 120 mg taurine and 120 mg carnitine per 1500 kcals.
By way of example, and not limitation, an example 5 of the composition of the present will now be given.
COMPOSITION:
1000 ml Protein (Nx5.8) g 40.00 Carbohydrate 9 290.00 Fat 9 21.20 Minerals 9 8.00 Moisture 9 761.60 Energy Kcal1500.00 KJ6280.00 Vitamin A IU5000.00 mcg RE 1500.00 Vitamin D IU400.00 mcg1 0.00 Vitamin E IU 30.00 Vitamin K mcg120.00 Vitamin C mg 96.00 Thiamine (B1) mg 1.52 Ribofiavin (B2) mg 1.72 Niacin (PP) mg 20.p0 Vitamin B6 mg 2.00 Folic Acid mcg400.00 . `
Pantoth. Acid mg 10.00 Vitamin B12 mcg6.00 Biotin mcg300.00 Choline mg400.00 Taurine mg120.00 L-Carnitine mg120.00 Soaiium mg320.00 , ~ . . . . . .
,~ i 1 ~ 9 1 7 Potassium mg1320.00 Chloride mg1500.00 Caicium mg1000.00 Phosphorus mg1000.00 Magnesium mg400.00 Copper mg 2.00 lodine mcg152.00 Iron mg 18.00 Manganese mg 4.00 1 0 Zinc mg 15.20 Density= 1125g/Liter pH 6.8 FAT COMPOSITION:
1 5 1000 ml Total fat 9 21.2 MCT 9 13.76 Canola Oil 9 4.16 C:orn Oil 9 1.12 Milk Fat 9 1.12 Lecithin 9 1.12 Linoleic Acid 9 1.58 Vitamin E IU 30 Vltamin E: linolelc = 19 lU/gm -~ ~:
PERCENTAGE COMPOSITION OF FAT: -MCT 66% (63% of energy from fat~
Canola oll 19% (20% of energy from fat) Corn oil 5% (5.5% of energy from fat) 3 0 Milk Fat 5% (5.5% of energy from fat) Lecithin _~ (6% of enerav from fat) Total 100% Total 100%
ll6~7 FATTY ACID COMPOSITION (CALCULATED FROM STANDARD VALUES):
Fany acid composition Calculated from standard values (% of total fattv acids) Saturated Butyric acid (C4:0)0.13 0.03 Caproic acid (C6:0)0.72 0.14 Caprylic acid (C8:0) 38.36 7.42 Capric acid (C,0:0) 27.02 5.23 1 0 Lauric acid (cl2 o) 1.43 0.28 Myristic acid (Cl4:0) 0.47 o.09 Palmitic acid (Cl6:0) 2.80 0.S4 Stearic acid (C,8:0) 1.16 0.22 Total saturated 72.09 l3.95 Unsaturated Palmitoleic acid (C,6:1) 0.25 0.05 Oleic acid (C~B:1) 16.74 3.24 Linoleic acid (C,a:2) 8.38 1.62 Linolenic acid (Cl8:3) 2.16 0.42 Erucic acid (C22:1) 0 40 0.08 Total unsaturated 27.93 5.41 Protein Source: Free Amino Acid 77%
Whey 23%
Nitrogen to energy ratio (9 N/kcal): 1:217 Nitrogen to non-protein energy ratio (9 N/kcal): 1 :194 ' :" -2 1 1 ~ 9 Ll 7 AMINO ACID COMPOSITION:
~QQ~ç~ 1500 Kcal250 ml1000 ml L-Leucine gm 0.62 9.32 2.33 9.32 i-lsoleucine gm 0.51 7.72 1.93 7.72 L-Valine gm 0.41 6.20 1.55 6.20 L-Lysine gm 0.33 5.00 1.25 5.00 L-Arginine gm 0.32 4.80 1.20 4.80 L-Prollne gm 0.17 2.48 0.62 2.48 L-Glutamic acid gm 0.14 2.08 0.52 2.08 1 0 L-Alanine gm 0.13 1.88 0.47 1.88 L-Threonine gm o.10 1.s2 0.38 1.52 L-Histidine gm 0.10 1.44 0.36 1.44 L-Aspartic acid gm 0.07 1.04 0.26 1.04 Glycine gm 0.05 0.76 0.19 0.76 L-Serine gm 0.04 0.64 0.16 0.64 L-Methionine gm 0.04 0.56 0.14 0.56 L-Phenylalanine gm 0.03 0.40 0.10 0.40 ~ -L-Tyrosine gm 0.02 0.32 0.08 0.32 L-Tryptophane gm 0.02 0.24 0.06 0.24 L-Cystine gm 0.01 0.16 0.04 0.16 MAJOR MINERALS
100 Kcal 1soo Kcal2s0 ml Sodium mg21.33 320.00 80.00320.00 mmol 0.93 13.92 3.48 13.92 2 5 Potassium mg88.00 1320.00 330.001320.00 mmol 2.25 33.76 8.44 33.76 Chloride mg100.00 1500.00 375.001500.00 mmol 2.82 42.32 10.58 42.32 Calcium mg66.67 1000.00 250.001000.00 3 0 mmol 1.67 25.00 6.25 25.00 Phosphorus mg66.67 1000.00 250.001000.00 mmol 2.15 32.24 8.06 32.24 .
!3 !1 7 Magnesium mg 26.67400.00100.00400.00 mmol1.1016.44 4.11 16.44 Ba~e excess (1) mmol0.365.36 1.34 5.36 Renal sol~e load (2)mOsm21.20318.00 29.50 318.00 ELECTROLYTE RATIOS
Na/K (3) : 0.4 (Na ~ K)/CI (3) : 1.1 Ca/P (4) : 1.0 FORMULA OSMOLARITY/OSMOLALITY
Osmolarity 525 mOsm/1 Osmolality 690 mOsm/kg H2O
The osmolarity of such liquid diets is important.
Because hypertonic diets are a cause of diarrhea and intestinal discomfort in patient on enteral feeding, hyperosmolar formulas initially have to be fed diluted and only gradually be increased to full strength. When a patient is not taking a formula full strength, he meets neither his energy nor his protein, mineral, and vitamin needs. There is also evidence that hypertonic foods have a deleterious effect on the gastrointestinal tract.
The osmolarity of the composition is preferably at least 500 mOsm/l and, in a preferred embodiment, 525 mOsm/l (690 mOsm/kg of water). This is hypertonic with serum (osmolarity 260-280 mOsm/ml, osmolali'y 280-300 mosmol/kg of water) and should not be expected to cause any problems.
It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present invention and without diminishing its attendant advantages. It is therefore intended that such changes and modifications be covered by the appended claims.
Claims (28)
1. A ready-to-use composition for providing nutritional support for a hepatic patient, that does not require reconstitution and can be stored in a liquid form comprising:
a lipid source;
a carbohydrate source; and a protein source that comprises at least 25% by protein content free amino acids.
a lipid source;
a carbohydrate source; and a protein source that comprises at least 25% by protein content free amino acids.
2. The composition of Claim 1 wherein:
the protein comprises approximately 6 to about 16%
of the caloric content of the composition;
the lipid comprises approximately 6 to about 18% of the caloric content; and the carbohydrates comprise approximately 66 to about 88% of the caloric content of the composition.
the protein comprises approximately 6 to about 16%
of the caloric content of the composition;
the lipid comprises approximately 6 to about 18% of the caloric content; and the carbohydrates comprise approximately 66 to about 88% of the caloric content of the composition.
3. The composition of Claim 1 wherein the protein includes whey.
4. The composition of Claim 1 wherein the free amino acids comprise a majority of the protein source.
5. The composition of Claim 1 wherein the amino acids are comprised of 40% to 60% branched chain amino acids.
6. The composition of Claim 1 wherein the amino acids include less than 3% aromatic and ammonia-generating amino acids.
7. The composition of Claim 1 including at least 100% of the U.S. RDA of all vitamins per 1500 Kcals of composition.
8. The composition of Claim 1 wherein the lipid source is a mixture of medium chain triglycerides and long chain fatty acids.
9. The composition of Claim 8 wherein the ratio of medium chain triglycerides to long chain fatty acids is 1:1 to 3:1.
10. The composition of Claim 1 wherein the lipid source has a ratio of omega-6 to omega-3 fatty acids of 4:1.
11. The composition of Claim 1 wherein the composition provides 100% of the U.S. RDA for calcium, phosphorus, magnesium, copper, iodine, iron, and zinc per 1500 Kcals of composition.
12. The composition of Claim 1 wherein the osmolarity of the composition is at least 500 mOsm/L.
13. The composition of Claim 1 wherein the free amino acids include: leucine; isoleucine; valine;
lysine; arginine; proline; glutamic acid; alanine;
threonine; histidine; aspartic acid; glycine; serine;
methionine; phenylalanine; tyrosine; tryptophane; and cystine.
lysine; arginine; proline; glutamic acid; alanine;
threonine; histidine; aspartic acid; glycine; serine;
methionine; phenylalanine; tyrosine; tryptophane; and cystine.
14. A shelf stable ready-to-use liquid composition for providing nutritional support to a patient comprising:
approximately 6 to about 16%, by caloric content of the composition, of a protein that comprises a majority of its content as free crystalline amino acids;
approximately 6 to about 25%, by caloric content of the composition, of a lipid source; and approximately 66 to about 88% by caloric content the composition as a carbohydrate source.
approximately 6 to about 16%, by caloric content of the composition, of a protein that comprises a majority of its content as free crystalline amino acids;
approximately 6 to about 25%, by caloric content of the composition, of a lipid source; and approximately 66 to about 88% by caloric content the composition as a carbohydrate source.
15. The composition of Claim 14 wherein the protein includes whey.
16. The composition of Claim 15 wherein the whey comprises approximately 25% to about 40% of the protein source.
17. The composition of Claim 14 wherein the amino acids comprise 40% to 60% branched chain amino acids.
18. The composition of Claim 14 wherein the amino acids include less than 3% aromatic and ammonia-generating amino acids.
19. The composition of Claim 14 wherein the free amino acids include: leucine; isoleucine; valine;
lysine; arginine; proline; glutamic acid; alanine;
threonine; histidine; aspartic acid; glycine; serine;
methionine; phenylalanine; tyrosine; tryptophane; and cystine.
lysine; arginine; proline; glutamic acid; alanine;
threonine; histidine; aspartic acid; glycine; serine;
methionine; phenylalanine; tyrosine; tryptophane; and cystine.
20. The composition of Claim 14 including at least 100% of the U.S. RDA of all vitamins per 1500 Kcals of composition.
21. The composition of Claim 14 wherein the lipid source is a mixture of medium chain triglycerides and long chain fatty acids.
22. The composition of Claim 21 wherein the ratio of medium chain triglycerides to long chain fatty acids is 1:1 to 3:1.
23. The composition of Claim 14 wherein the composition provides 100% of the U.S. RDA for calcium, phosphorus, magnesium, copper, iodine, iron, and zinc per 1500 Kcals of composition.
24. A method for preparing a shelf stable liquid ready-to-use nutritional product comprising the steps of:
providing a lipid source;
providing a carbohydrate source;
providing a protein source that includes free crystalline amino acids; and adding to the protein source whey protein in an amount that comprises less than a majority of the protein source but is sufficient to stabilize a solution that comprises the combination of the lipid, carbohydrate, and protein source.
providing a lipid source;
providing a carbohydrate source;
providing a protein source that includes free crystalline amino acids; and adding to the protein source whey protein in an amount that comprises less than a majority of the protein source but is sufficient to stabilize a solution that comprises the combination of the lipid, carbohydrate, and protein source.
25. A method for providing nutrition to a hepatic patient comprising the steps of:
administering enterally to a patient with liver disease a shelf stable composition that does not require reconstitution that comprises:
approximately 6 to about 16%, by caloric content of the composition, of a protein that comprises a majority of its content as free crystalline amino acids;
approximately 6 to about 25%, by caloric content of the composition, of a lipid source; and approximately 66 to about 88%, by caloric content of the composition, as a carbohydrate source.
administering enterally to a patient with liver disease a shelf stable composition that does not require reconstitution that comprises:
approximately 6 to about 16%, by caloric content of the composition, of a protein that comprises a majority of its content as free crystalline amino acids;
approximately 6 to about 25%, by caloric content of the composition, of a lipid source; and approximately 66 to about 88%, by caloric content of the composition, as a carbohydrate source.
26. The method of Claim 25 wherein the composition is administered through a naso-gastric feeding tube.
27. The method of Claim 25 wherein the composition is administered by having the patient drink same.
28. The method of Claim 25 wherein the composition provides complete nutritional support for the patient.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/028,373 US5571783A (en) | 1993-03-09 | 1993-03-09 | Composition and method for treating patients with hepatic disease |
| US028,373 | 1993-03-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2116947A1 true CA2116947A1 (en) | 1994-09-10 |
Family
ID=21843089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002116947A Abandoned CA2116947A1 (en) | 1993-03-09 | 1994-03-03 | Composition and method for treating patients with hepatic disease |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5571783A (en) |
| EP (1) | EP0614616B1 (en) |
| JP (1) | JPH0748270A (en) |
| AT (1) | ATE209864T1 (en) |
| AU (1) | AU5763094A (en) |
| CA (1) | CA2116947A1 (en) |
| DE (1) | DE69429297T2 (en) |
| DK (1) | DK0614616T3 (en) |
| ES (1) | ES2167338T3 (en) |
| PT (1) | PT614616E (en) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9419345D0 (en) * | 1994-09-26 | 1994-11-09 | Sandoz Nutrition Ltd | Organic compounds |
| US5589468A (en) * | 1995-01-13 | 1996-12-31 | Clintec Nutrition Co. | Method for providing nutrition to elderly patients |
| US5656608B1 (en) * | 1995-02-23 | 2000-09-26 | Novartis Nutrition Ltd | Amino acid compositions and methods of treatment using same |
| GB9512100D0 (en) * | 1995-06-14 | 1995-08-09 | Sandoz Nutrition Ltd | Improvements in or relating to organic compounds |
| DE69607750T2 (en) * | 1995-02-23 | 2000-08-31 | Novartis Nutrition Ag | AMINO ACID COMPOSITIONS AND USE OF THE SAME CLINICAL FOOD |
| CA2173780A1 (en) * | 1995-06-01 | 1996-12-02 | Randy Grote | Method for providing nutrition in a variety of compositional forms |
| US5728678A (en) * | 1995-06-06 | 1998-03-17 | Nestec Ltd. | Method and composition for providing nutrition to a renal failure patient |
| JPH09194364A (en) * | 1996-01-22 | 1997-07-29 | Snow Brand Milk Prod Co Ltd | Vitamin a absorbefacient |
| BR9708656A (en) * | 1996-04-12 | 2000-01-04 | Beth Israel Hospital | Supplementary bar for diabetics |
| US5866555A (en) * | 1997-03-12 | 1999-02-02 | Beth Israel Deaconess Medical Center | Diabetic supplement bar |
| US5817329A (en) * | 1997-02-28 | 1998-10-06 | Gardiner; Paul T. | Nutritional supplement for increased muscle size and strength for body builders |
| IT1291126B1 (en) * | 1997-04-01 | 1998-12-29 | Sigma Tau Ind Farmaceuti | SOLID COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION INCLUDING NON-HYGROSCOPIC SALTS OF L-CARNITINE AND L-CARNITINE ALCANOYLS |
| ES2132021B1 (en) * | 1997-05-28 | 2000-02-16 | Riera Simon Schwartz | AMINO ACID FORMULAS FOR PERSONS OF THE OLDER AGE AND PROCEDURE FOR THE CALCULATION OF THE SAME. |
| FR2765481B1 (en) * | 1997-07-07 | 2000-12-08 | Jacques Bogart Sa | AMINO-LIPIDIC VITAMIN COMPLEX |
| US20040022827A1 (en) * | 1997-09-30 | 2004-02-05 | Chugai Seiyaku Kabusiki Kaisha | Remedy for hepatopathy |
| CA2439293A1 (en) | 2001-03-05 | 2002-09-12 | Stephen P. Ernest | Enteral formulation |
| ATE369045T1 (en) * | 2001-11-26 | 2007-08-15 | Nestec Sa | STORAGE-Stable FOOD PRODUCT CONTAINING WHEY PROTEIN, METHOD FOR ITS PRODUCTION AND USE |
| US20030105104A1 (en) * | 2001-11-27 | 2003-06-05 | Burzynski Stanislaw R. | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| AU2002367129A1 (en) * | 2001-12-25 | 2003-07-15 | Ajinomoto Co., Inc. | Organ fibrosis inhibitors |
| MXPA04012641A (en) * | 2002-06-21 | 2005-08-15 | Oreal | Use of taurine or derivatives thereof for the treatment of alopecia. |
| EP1541141A1 (en) * | 2002-08-30 | 2005-06-15 | Ajinomoto Co., Inc. | Therapeutic agent for hepatic disease |
| US20040219188A1 (en) * | 2003-05-02 | 2004-11-04 | Comer Gail M. | Composition and methods for nutritional management of patients with hepatic disease |
| US7256202B2 (en) * | 2003-12-31 | 2007-08-14 | Halow George M | Composition and method for treatment of hepatic encephalopathy |
| US20060089412A1 (en) * | 2004-10-18 | 2006-04-27 | Ajinomoto Co. Inc. | Pharmaceutical composition for the treatment of non-alcoholic fatty liver disease |
| WO2006056794A1 (en) * | 2004-11-26 | 2006-06-01 | Ucl Business Plc | Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy |
| JP2006241140A (en) * | 2005-02-01 | 2006-09-14 | Otsuka Pharmaceut Factory Inc | Nutritive composition for hepatic disease |
| CN101405054B (en) * | 2005-12-15 | 2013-07-17 | 雀巢技术公司 | Compositions and methods for preserving brain function |
| AU2006340316B2 (en) * | 2006-03-23 | 2013-03-28 | Nestec S.A. | High-calorie nutritional supplement |
| US20090092657A1 (en) * | 2007-10-09 | 2009-04-09 | Douglas Burke | Amino acid combinant omega oil aphrodisiac |
| GB2473390B (en) | 2008-07-07 | 2012-09-26 | Pentec Health Inc | Nutritive compositions and methods of using same |
| SG10202010988WA (en) | 2009-04-03 | 2020-12-30 | Ocera Therapeutics Inc | L-ornithine phenyl acetate and methods of making thereof |
| EA201691430A1 (en) | 2009-06-08 | 2017-02-28 | ЮСиЭл БИЗНЕС ПиЭлСи | TREATMENT OF PORTAL HYPERTENSION AND RESTORATION OF LIVER FUNCTION BY MEANS OF L-ORNITINPHENYL ACETATE |
| MX2012006923A (en) * | 2009-12-18 | 2012-07-10 | Stokely Van Camp Inc | Protein recovery beverage. |
| GB2489163A (en) * | 2010-01-04 | 2012-09-19 | Pentec Health Inc | Nutritive compositions and methods of using same |
| CN105747218A (en) * | 2010-06-28 | 2016-07-13 | 雀巢产品技术援助有限公司 | Hypocaloric, high protein nutritional compositions and methods of using same |
| KR101213825B1 (en) | 2010-07-16 | 2012-12-18 | 서울대학교산학협력단 | Composition for the prevention and treatment of fatty liver diseases containing serine as an active ingredient |
| NZ609191A (en) | 2010-10-06 | 2015-06-26 | Ocera Therapeutics Inc | Methods of making l-ornithine phenyl acetate |
| US20210176999A1 (en) | 2011-04-17 | 2021-06-17 | Omega Foods, LLC | Prepared foods having high efficacy omega-6/omega-3 balanced polyunsaturated fatty acids |
| WO2013133691A1 (en) * | 2012-03-09 | 2013-09-12 | N.V. Nutricia | Liquid nutritional composition comprising free amino acids |
| ES2769000T3 (en) | 2014-11-24 | 2020-06-24 | Ucl Business Ltd | Treatment of diseases associated with the activation of liver stellate cells using ammonia-reducing therapies |
| CA2995823A1 (en) | 2015-08-18 | 2017-02-23 | Ocera Therapeutics, Inc. | Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate |
| JOP20190146A1 (en) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | Amino acid compositions and methods for the treatment of liver diseases |
| KR20200024145A (en) | 2017-05-11 | 2020-03-06 | 오세라 테라퓨틱스, 아이엔씨. | Method for preparing L-ornithine phenyl acetate |
| CN111295187A (en) | 2017-08-14 | 2020-06-16 | 胺细拉健康公司 | Amino acid composition for treating liver diseases |
| MA52971A (en) | 2018-06-20 | 2021-04-28 | Axcella Health Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FAT INFILTRATION IN THE MUSCLE |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3697287A (en) * | 1969-01-28 | 1972-10-10 | Morton Norwich Products Inc | Amino acid food composition |
| US3698912A (en) * | 1969-07-01 | 1972-10-17 | Morton Norwich Products Inc | Process for making nutrient composition |
| US3773930A (en) * | 1971-03-23 | 1973-11-20 | Johnson & Johnson | Amino acid composition |
| IT987278B (en) * | 1973-05-11 | 1975-02-20 | Snam Progetti | PROCEDURE FOR THE PREPARATION OF L CARBAMIL AMINO ACIDS AND THE CORRESPONDING L AMINO ACIDS |
| US3920838A (en) * | 1973-09-04 | 1975-11-18 | Flatt Jean Pierre | Amino acid therapy |
| US4100293A (en) * | 1974-04-15 | 1978-07-11 | The Johns Hopkins University | Treatment of hepatic disorders with therapeutic compositions comprising keto analogs of essential amino acids |
| GB1511302A (en) * | 1974-04-15 | 1978-05-17 | Univ Johns Hopkins | Pharmaceutical compositions comprising amino acid analogues |
| US3950529A (en) * | 1975-02-03 | 1976-04-13 | Massachusetts General Hospital | Amino acid formulations for patients with liver disease and method of using same |
| US4098910A (en) * | 1975-02-19 | 1978-07-04 | International Flavors & Fragrances Inc. | Flavoring with certain 3-furyl alkyl disulfides |
| US4025650A (en) * | 1975-11-24 | 1977-05-24 | Control Drug, Inc. | Method and composition for preventing nutritional deficiency |
| US4053589A (en) * | 1975-11-24 | 1977-10-11 | Control Drug Inc. | Method of treating nutritional deficiency during cardiac cachexia, diabetes, hypoglycemia, gastroenterology, lipid, cell glycogen and keratin-related skin conditions and alcoholism |
| US4124448A (en) * | 1976-04-09 | 1978-11-07 | The Regents Of The University Of Minnesota | Process for the large scale production of human growth hormone by serial secondary suspension culture |
| US4288546A (en) * | 1976-04-09 | 1981-09-08 | The Regents Of The University Of Minnesota | Process for the large scale production of pituitary hormones by serial secondary suspension culture |
| US4082613A (en) * | 1976-04-23 | 1978-04-04 | The Regents Of The University Of Minnesota | Process for the production of insulin by genetically transformed fungal cells |
| US4288542A (en) * | 1976-04-30 | 1981-09-08 | The Upjohn Company | Radioenzymatic assay of catecholamines |
| GB1592791A (en) * | 1977-01-07 | 1981-07-08 | Radiochemical Centre Ltd | Selenium- or tellurium-containing bile acids and derivatives thereof |
| DE2750159C3 (en) * | 1977-11-09 | 1980-05-22 | Lentia Gmbh, Chem. U. Pharm. Erzeugnisse - Industriebedarf, 8000 Muenchen | Infusion solution for the treatment of hepatic encephalopathy and a process for the manufacture thereof |
| US4320146A (en) * | 1978-03-17 | 1982-03-16 | The Johns Hopkins University | Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids |
| JPS5536457A (en) * | 1978-09-08 | 1980-03-14 | Ajinomoto Co Inc | Amino acid infusion |
| JPS5564512A (en) * | 1978-11-11 | 1980-05-15 | Kanebo Ltd | Cosmetic composition of oil-in-water emulsion |
| US4391909A (en) * | 1979-03-28 | 1983-07-05 | Damon Corporation | Microcapsules containing viable tissue cells |
| US4352814A (en) * | 1979-04-18 | 1982-10-05 | The Johns Hopkins University | Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs |
| US4254103A (en) * | 1979-06-08 | 1981-03-03 | Institul de Cercetari Chimicofarmaceutice | Hepatoprotector Factor (HF) and method of treatment |
| US4216065A (en) * | 1979-06-18 | 1980-08-05 | University Of Delaware | Bio-selective electrode probes using tissue slices |
| US4252822A (en) * | 1979-12-26 | 1981-02-24 | Children's Hospital Medical Center | Method for treating phenylketonuria |
| USRE30753E (en) * | 1980-01-07 | 1981-09-29 | The Regents Of The University Of Minnesota | Process for the large scale production of human growth hormone by serial secondary suspension culture |
| US4284647A (en) * | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| JPS5729949A (en) * | 1980-07-30 | 1982-02-18 | Nippon Koutai Kenkyusho:Kk | Determination of sugar branch related to cancer and diagnostic technique of cancer |
| JPS5852634B2 (en) * | 1980-12-05 | 1983-11-24 | 株式会社林原生物化学研究所 | Production method of urokinase |
| US4529543A (en) * | 1981-02-24 | 1985-07-16 | Newport Pharmaceuticals International | Hepatosin |
| US4898879A (en) * | 1981-06-29 | 1990-02-06 | Baxter International Inc. | Nurtitional composition for management of hepatic failure |
| JPS58126767A (en) * | 1982-01-22 | 1983-07-28 | Ajinomoto Co Inc | Elemental diet for hepatopathic patient |
| US4612302A (en) * | 1983-11-14 | 1986-09-16 | Brigham And Women's Hospital | Clinical use of somatostatin analogues |
| FR2556594B1 (en) * | 1983-12-20 | 1988-09-09 | Synthelabo | AMINO ACID SOLUTIONS |
| CH658165A5 (en) * | 1984-01-04 | 1986-10-31 | Nestle Sa | FOOD PRODUCT EFFECTIVE IN THE TREATMENT OF LEPROSY. |
| US4703062A (en) * | 1984-01-16 | 1987-10-27 | Baxter Travenol Laboratories, Inc. | Parenteral nutrition with medium and long chain triglycerides |
| US4704394A (en) * | 1984-04-25 | 1987-11-03 | Technology Unlimited, Inc. | Treatment for hyperactivity |
| US4687782A (en) * | 1984-12-10 | 1987-08-18 | Nutri-Fuels Systems, Inc. | Nutritional composition for enhancing skeletal muscle adaptation to exercise training |
| DE3521226A1 (en) * | 1985-02-08 | 1986-08-14 | Hoechst Ag, 6230 Frankfurt | GENES FOR BIOLOGICALLY ACTIVE PROTEINS |
| JPH0667831B2 (en) * | 1986-01-13 | 1994-08-31 | 森永乳業株式会社 | Amino acid composition for improving hepatic substance synthesis dysfunction |
| US4863898A (en) * | 1986-02-06 | 1989-09-05 | Albion International, Inc. | Amino acid chelated compositions for delivery to specific biological tissue sites |
| US4920098A (en) * | 1986-09-17 | 1990-04-24 | Baxter International Inc. | Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases |
| US5053387A (en) * | 1987-02-20 | 1991-10-01 | Shriners Hospitals For Crippled Children | Omega-3 fatty acids in traumatic injury treatment |
| US4780309A (en) * | 1987-06-16 | 1988-10-25 | Warner-Lambert Company | Edible aerosol foam compositions and method of preparing same |
| CA1333471C (en) * | 1988-04-29 | 1994-12-13 | Gustavo Bounous | Whey protein concentrate as food supplement |
| JPH02145170A (en) * | 1988-11-29 | 1990-06-04 | Nippon Oil & Fats Co Ltd | Liquid protein assistant food |
| US5221668A (en) * | 1992-02-26 | 1993-06-22 | Abbott Laboratories | Nutritional product for trauma and surgery patients |
-
1993
- 1993-03-09 US US08/028,373 patent/US5571783A/en not_active Expired - Lifetime
-
1994
- 1994-03-03 ES ES94103163T patent/ES2167338T3/en not_active Expired - Lifetime
- 1994-03-03 DE DE69429297T patent/DE69429297T2/en not_active Expired - Lifetime
- 1994-03-03 DK DK94103163T patent/DK0614616T3/en active
- 1994-03-03 CA CA002116947A patent/CA2116947A1/en not_active Abandoned
- 1994-03-03 EP EP94103163A patent/EP0614616B1/en not_active Expired - Lifetime
- 1994-03-03 PT PT94103163T patent/PT614616E/en unknown
- 1994-03-03 AT AT94103163T patent/ATE209864T1/en not_active IP Right Cessation
- 1994-03-07 AU AU57630/94A patent/AU5763094A/en not_active Abandoned
- 1994-03-09 JP JP6038274A patent/JPH0748270A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0748270A (en) | 1995-02-21 |
| DK0614616T3 (en) | 2002-01-14 |
| US5571783A (en) | 1996-11-05 |
| EP0614616B1 (en) | 2001-12-05 |
| ES2167338T3 (en) | 2002-05-16 |
| DE69429297D1 (en) | 2002-01-17 |
| ATE209864T1 (en) | 2001-12-15 |
| EP0614616A3 (en) | 1995-07-26 |
| DE69429297T2 (en) | 2002-10-24 |
| EP0614616A2 (en) | 1994-09-14 |
| AU5763094A (en) | 1994-09-15 |
| PT614616E (en) | 2002-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5571783A (en) | Composition and method for treating patients with hepatic disease | |
| US5728678A (en) | Method and composition for providing nutrition to a renal failure patient | |
| US8703725B2 (en) | Nutritional compositions | |
| EP0587824B1 (en) | Nutritional product for persons receiving renal dialysis | |
| US6544547B2 (en) | Nutritional composition containing methionine | |
| US6376544B2 (en) | Nutritional product for a person having renal failure | |
| Halsted | Nutrition and alcoholic liver disease | |
| US5719133A (en) | Adolescent dietary composition | |
| Heidland et al. | Expert working group report on nutrition in adult patients with renal insufficiency (Part 2 of 2) | |
| US8377876B2 (en) | Pediatric amino acid solution for parenteral nutrition | |
| Muñoz | Nutritional therapies in liver disease | |
| EP0312612B1 (en) | Nutritive emulsion | |
| Center | Nutritional support for dogs and cats with hepatobiliary disease | |
| CA2215692C (en) | Method of modulating microcirculation | |
| JPH031287B2 (en) | ||
| US20110230400A1 (en) | Nutritional composition for wound healing | |
| Ambühl | Protein intake in renal and hepatic disease | |
| JP4011638B2 (en) | Oral enteral nutrition composition | |
| JPH0328403B2 (en) | ||
| RU2335927C2 (en) | Nutrient compositions enriched with leucine | |
| Alpers et al. | Approach to the patient requiring nutritional supplementation | |
| Watford et al. | Dietary glutamine suppresses endogenous glutamine turnover in the rat | |
| Guenter et al. | Hepatic disease: Nutritional implications | |
| Stein et al. | Amino acids–Guidelines on Parenteral Nutrition, Chapter 4 Aminosäuren–Leitlinie Parenterale Ernährung, Kapitel 4 | |
| CA2163379A1 (en) | Nutritional composition containing improved dietary nitrogen component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |